fStAx-33

General Information


DRACP ID  DRACP05944

Peptide Name   fStAx-33

Sequence  XPQⓍILDⓍHVRRVWR

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Stapled Peptides β-catenin inhibitor



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  β-catenin

Affinity  Kd=16±2 nM

Mechanism  Inhibit wnt/β-catenin signaling pathway

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ(4) and Ⓧ (8) are cross-linked by hydrocarbon stapling

N-terminal Modification  FITC

C-terminal Modification  Amidation

Other Modification  X=PEG1, [2-(2-aminoethoxy)ethoxy]acetyl; Ⓧ=(S)-2-(4'-pentenyl)alanine

Chiral  L



Physicochemical Information


Formula  C71H109N25O13

Absent amino acids  ACEFGKMNSTY

Common amino acids  R

Mass  188070

Pl  12.2

Basic residues  4

Acidic residues  1

Hydrophobic residues  5

Net charge  3

Boman Index  -4343

Hydrophobicity  -63.33

Aliphatic Index  90.67

Half Life 
  /

Extinction Coefficient cystines  5500

Absorbance 280nm  392.86

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23071338

Title  Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin

Doi 10.1073/pnas.1208396109

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.